Heat Biologics Inc. and Oncosec Medical Inc. are joining forces to evaluate the preclinical efficacy of combining Heat's tumor-specific cytotoxic T-cell immunotherapy with Oncosec's Immunopulse intratumoral DNA delivery platform in a bid to expand the impact of their technologies for the benefit of people with cancer.